Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

March 23, 2011
S0931
Renal Cancer
Alexander Hantel, MD

Naperville, Plainfield

Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.

Sponsor: SWOG (formerly the Southwest Oncology Group)

http://clinicaltrials.gov/ct2/show/NCT01120249?term=NCT01120249&rank=1

  • Histologically or cytologically confirmed renal cell carcinoma
  • Have undergone a full surgical resection (radical nephrectomy or partial nephrectomy) including removal of all clinically positive nodes, surgical margins must be negative
  • Patients with positive renal vein margins are eligible unless there is invasion of the renal vein wall at the margin (provided no other margins are positive)
  • Patients must be registered within 84 days after the date of the first surgical resection of the first tumor
  • No evidence of residual or metastatic renal cell cancer on CT scan of the chest, abdomen, and pelvis (all with oral and IV contrast) performed after nephrectomy and within 28 days before registration

10-12 years

Accepting Participants
Interventional
III
Kathy Seymour, BSN
630-646-6050
630-646-6110
630-646-6075